Tumor-associated macrophage

Codiak Presents Preclinical Data on exoASO™-STAT6 and exoASO™-C/EBPβ Programs at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

Retrieved on: 
Thursday, November 10, 2022
Therapeutic index, Histology, ASO, Biology, Colorectal cancer, Tams, Exosome, HCC, STAT6, Infection, Engineering, Security (finance), MDSC, Tumor microenvironment, IL4R, U.S. Securities and Exchange Commission, Cancer, Neoplasm, Factor X, Liver, Asos, Patient, NSCLC, CEO, Glycoprotein, RNA transfection, Private Securities Litigation Reform Act, Protein, PK, Peptide, Liver disease, Mouse, Monocyte, Myelocyte, Toxicity, Pharmacology, Tropism, Phenotype, PD, Trial of the century, GLOBE, The Cancer Genome Atlas, Myeloid-derived suppressor cell, Database, Large-cell lung carcinoma, NASDAQ, TCGA, Biomarker, Tumor-associated macrophage, Therapy, SITC, Pharmaceutical industry, Vaccine, Medical imaging

CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced new preclinical data from its exoASO™-STAT6 and exoASO™-C/EBPβ programs. exoASO-STAT6, an engineered exosome precision medicine candidate designed to selectively deliver antisense oligonucleotides to disrupt STAT6 signaling in tumor-associated macrophages (TAMs) and induce an anti-tumor immune response, demonstrated a strong preclinical pharmacokinetic (PK) and pharmacodynamic (PD) profile in preclinical models. Codiak has also identified PD biomarkers with clinical translational potential and described a rationale for selecting cancer subtypes that could benefit from treatment with exoASO-STAT6.

Key Points: 
  • Codiak has also identified PD biomarkers with clinical translational potential and described a rationale for selecting cancer subtypes that could benefit from treatment with exoASO-STAT6.
  • Taken together, these data presented at SITC paint a compelling picture of the potential of our programs and our platform.
  • In multiple in vivo preclinical studies, exoASO-STAT6 demonstrated potent single agent activity, including >90% tumor growth inhibition and 50-80% complete responses.
  • High levels of C/EBP expression are associated with poor prognosis in multiple cancers, including non-small cell lung cancer (NSCLC).

Sensei Biotherapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights

Retrieved on: 
Tuesday, November 8, 2022
GLOBE, Review, Investigational New Drug, IND, Northwest Biotherapeutics, Research and development, Tumor microenvironment, Immunosuppression, Annual general meeting, Nasdaq, Cytokine release syndrome, Immunotherapy, Risk, Mouse, Primate, KOL, Society for Immunotherapy of Cancer, ATP, R, Cancer, Translation, PD-1, Survival, Pharmacokinetics, Company, CD39, The Year's Best Science Fiction: Twenty-Sixth Annual Collection, Clinical trial, Tumor-associated macrophage, Poster, Research, Conference, ET, Patient, GMP, Therapy, Administration, Society, NHP, SITC, Vaccine, Pharmaceutical industry, Fine chemical, Cryptocurrency, Science, VSIG4, Sensei

BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today reported financial results for the third quarter ended September 30, 2022 and provided recent business updates.

Key Points: 
  • Recent updates for SNS-101 include:
    On Friday, November 11, 2022, Sensei will present new preclinical data at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, being held in Boston, MA.
  • On Monday, November 21, 2022, Sensei will host a virtual KOL webinar Lessons from VISTA: New Strategies to Address an Important Immune Checkpoint.
  • Research and Development (R&D) Expenses: R&D expenses were $9.2 million for the quarter ended September 30, 2022, compared to $6.4 million for the quarter ended September 30, 2021.
  • Net Loss: Net loss was $13.4 million for the quarter ended September 30, 2022, compared to $9.7 million for the quarter ended September 30, 2021.

Navidea Biopharmaceuticals Announces Details of Presentation at Upcoming Society for Immunotherapy of Cancer Annual Meeting

Retrieved on: 
Monday, November 7, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Paclitaxel, Review, Coronavirus, Society, SEC, TAM, Risk, NYSE, Drug discovery, Immunotherapy, Biopharmaceutical, Securities Exchange Act of 1934, Securities Act of 1933, Tumor-associated macrophage, CD86, Disease, SITC, Forward-looking statement, Abstract, NYSE American, Neoplasm, Convention center, History, CD163, Technetium-99m, Boston Convention and Exhibition Center, Investigational New Drug, Health, Decision-making, Phenotype, Toxicity, CD80, Wound healing, Research, Annual report, Macrophage, Pharmaceutical industry, Cancer

The results will be presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) to be held at the Boston Convention & Exhibition Center in person and virtually November 8-12, 2022 in Boston, MA.

Key Points: 
  • The results will be presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) to be held at the Boston Convention & Exhibition Center in person and virtually November 8-12, 2022 in Boston, MA.
  • These details were embargoed by SITC until the week of the meeting.
  • Abstract title and session information can be found on the SITC Annual Meeting website at: https://www.sitcancer.org/2022/home .
  • Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics.

Bolt Biotherapeutics to Present Preclinical Data on BDC-3042, Dectin-2 Targeting Agonistic Antibody, at the SITC Annual Meeting

Retrieved on: 
Monday, November 7, 2022
Neoplasm, Cytokine, Nivolumab, Publication, Boston Convention and Exhibition Center, Bristol Myers Squibb, GLOBE, Society for Immunotherapy of Cancer, Poster, Chemokine, Nasdaq, Immunotherapy, Tams, Annual general meeting, Macrophage, ISAC, Doctor of Philosophy, Immune stimulating antibody conjugate, Tumor-associated macrophage, SITC, Convention center, Patient, Cancer, Pharmaceutical industry, Vaccine, IND

These new preclinical data highlight the strides we are making in the development of BDC-3042, our Dectin-2-targeting agonistic antibody, as we advance our IND-enabling activities, said Randall Schatzman, Ph.D., Chief Executive Officer of Bolt Biotherapeutics.

Key Points: 
  • These new preclinical data highlight the strides we are making in the development of BDC-3042, our Dectin-2-targeting agonistic antibody, as we advance our IND-enabling activities, said Randall Schatzman, Ph.D., Chief Executive Officer of Bolt Biotherapeutics.
  • We look forward to presenting these data to the SITC community and remain dedicated to developing novel treatments for patients with solid tumors.
  • Bolt Biotherapeutics pipeline candidates are built on the Companys deep expertise in myeloid biology and cancer drug development.
  • Bolt Biotherapeutics is advancing BDC-3042, an agonist antibody targeting Dectin-2, through IND-enabling studies.

Pionyr Immunotherapeutics’ MARCO-targeting Antibody Program, PY265, for Treatment of Solid Tumors Featured at SITC 2022

Retrieved on: 
Monday, November 7, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Immunosuppression, Cytokine, Research, New Enterprise Associates, Therapy, Tumor microenvironment, Growth, Transcription activator-like effector nuclease, Cancer, MARCO, Sofinnova, Mouse, Neoplasm, TME, Poster, Chemokine, Phosphorylation, Immunotherapy, Tams, Myelocyte, Gilead, TREM2, ADCC, TREM1, Gilead Sciences, CPI, MDSC, Society, SITC, Society for Immunotherapy of Cancer, Program, Tumor-associated macrophage, Pharmaceutical industry, Vaccine, Pionýr

By reprogramming myeloid cells, PY265 remodels the TME to unleash anti-tumor immunity and converts CPI-resistant tumors into treatment-responsive tumors.

Key Points: 
  • By reprogramming myeloid cells, PY265 remodels the TME to unleash anti-tumor immunity and converts CPI-resistant tumors into treatment-responsive tumors.
  • The poster will be available on the Pionyr company website after the completion of the SITC poster session.
  • Pionyr has developed a therapeutic platform called Myeloid TuningTM, a process that rebalances the tumor microenvironment (TME) to promote anti-tumor immunity.
  • Pionyr is exploiting novel target discovery and antibody generation platform technologies to create the next generation of immuno-oncology therapeutics after checkpoint inhibitors.

Enlivex to Present at the 4th Macrophage-Directed Therapies Summit

Retrieved on: 
Monday, October 3, 2022
Inflammation, Marketing, Human, Review, Regenerative medicine, CD47, Immunotherapy, Nasdaq, Private Securities Litigation Reform Act, Autoimmunity, Decision-making, Annual report, Risk, Immune system, U.S. Securities and Exchange Commission, Sepsis, Therapy, Tumor-associated macrophage, Safety, Animal, Program, Security (finance), GLOBE, Pharmaceutical industry

Nes-Ziona, Israel, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the Company), a clinical-stage macrophage reprogramming immunotherapy company, today announced that company management will participate in, and present at, the 4th Macrophage-directed Therapies Summit, which is taking place in Boston, Massachusetts from October 4-6, 2022.

Key Points: 
  • Nes-Ziona, Israel, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the Company), a clinical-stage macrophage reprogramming immunotherapy company, today announced that company management will participate in, and present at, the 4th Macrophage-directed Therapies Summit, which is taking place in Boston, Massachusetts from October 4-6, 2022.
  • Those interested in registering for the summit can do so here .
  • The 4th Macrophage-directed Therapies Summit will include presentations regarding approaches to target dont eat me signal, strategies to reprogram tumor-associated macrophages, and techniques to discover next-generation targeting methods to develop highly effective and controlled therapies.
  • Enlivex is a clinical stage immunotherapy company developing Allocetra, a universal, off-the-shelf cell therapy designed toreprogram macrophages into their homeostatic state.

Pionyr Immunotherapeutics Doses First Patient in Phase 1b Expansion Study of PY159

Retrieved on: 
Tuesday, September 20, 2022
Oncology, Health, General Health, Clinical Trials, Research, Science, Biotechnology, Therapy, PDAC, Safety, Immunosuppression, HNSCC, Sofinnova, Cytokine, Myelocyte, Immunotherapy, ADCC, NSCLC, Biomarker, Ovarian cancer, Colorectal cancer, Chemokine, Cancer, CRC, Pionýr, Patient, Tams, TREM2, Gilead, TREM1, Tumor-associated macrophage, TAM, Biology, Metastasis, Mab, TNBC, New Enterprise Associates, Head, Tumor microenvironment, Gilead Sciences, Research, Large-cell lung carcinoma, Pharmacokinetics, Myeloid tissue, Pembrolizumab, TME, Phosphorylation, Medical imaging, Pharmaceutical industry, Vaccine

In the Phase 1a dose escalation study, PY159 was well tolerated in doses up to 10 milligrams per kilogram and showed dose-proportional pharmacokinetics.

Key Points: 
  • In the Phase 1a dose escalation study, PY159 was well tolerated in doses up to 10 milligrams per kilogram and showed dose-proportional pharmacokinetics.
  • With these conclusions from Phase 1a, we are excited to begin this Phase 1b expansion study with leading clinical sites and investigators.
  • The multi-centered, US-based Phase 1a study evaluated the safety and tolerability of PY159 alone and in combination with pembrolizumab in multiple solid tumors and determined a recommended Phase 1b dose for expansion.
  • The Phase 1b study will evaluate PY159 administered alone and in combination with pembrolizumab in predefined tumor types.

OncoOne Expands Scientific Advisory Board Adding Three World-Renowned MIF and Macrophage Experts to Support Upcoming Clinical Programs

Retrieved on: 
Wednesday, September 7, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Harvard Medical School, Neoplasm, University, Breast cancer, HIV disease progression rates, CEO, Division, Research, Degenerative disease, Physician, University of Louisville School of Medicine, Immune tolerance, Microbiology, Macrophage, SAB, Dana–Farber Cancer Institute, International Association for Physicians in Aesthetic Medicine, QJM, Trinity, Phenotype, Department, Homeostasis, Biochemistry, Cytokine, Trinity College, Molecular medicine, Goal, Immunology, Hospital, Leadership, MIF, Company, Publication, Tumor-associated macrophage, Lead, Association, Quarterly Journal, Molecular genetics, Society for Immunotherapy of Cancer, Society, Trinity College Dublin, Patient, Pharmaceutical industry, Vaccine, Medicine, Immunotherapy, Cancer, Brigham

oxMIF is the disease-related and druggable isoform of the macrophage migration inhibitory factor (MIF), a critical driver in innate and adaptive immunity in cancers and immunology.

Key Points: 
  • oxMIF is the disease-related and druggable isoform of the macrophage migration inhibitory factor (MIF), a critical driver in innate and adaptive immunity in cancers and immunology.
  • The new members of the OncoOne Scientific Advisory Board include:
    Dr. Seamas Donnelly is Professor of Medicine at Trinity College Dublin.
  • He is a global leader in translational medicine with a research focus on the development of novel compounds as anti-inflammatory/anti-cancer therapies.
  • OncoOne seeks to overcome the limitations of targeting the macrophage migration inhibitory factor by harnessing the high tumor-specificity of the disease-related isoform of MIF, the oxidized macrophage migration inhibitory factor (oxMIF).

Bolt Biotherapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, August 10, 2022
U.S. Securities and Exchange Commission, ASCO, Chemokine, GLOBE, R, Cancer, Patent, Toxicity, Clinical trial, Security (finance), Annual report, Patient, Research and development, Tumor microenvironment, Nivolumab, American Association, Industry, American Society of Clinical Oncology, Annual general meeting, Immune stimulating antibody conjugate, Safety, Operation, Nasdaq, Forward-looking statement, Bolt, Tumor-associated macrophage, Growth, Myelocyte, AACR, Bristol Myers Squibb, Immunology, ISAC, Antibody, Association, Biomarker, Population, Clinical, IND, Society, CEA, Company, Therapy, Macrophage, Administration, USPTO, Pharmaceutical industry, Vaccine, Telescopic sight, Video game, Lease, Inc.

REDWOOD CITY, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2022 and provided a business update.

Key Points: 
  • REDWOOD CITY, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2022 and provided a business update.
  • The second quarter was one of continued progress, highlighted by steady clinical enrollment in our BDC-1001 monotherapy and combination dose-escalation studies.
  • Collaboration Revenue Collaboration revenue was $1.4 million for the quarter ended June 30, 2022, compared to $0 for the same quarter in 2021.
  • This represents 75% growth over the first quarter of 2022 as Bolt ramps up activities supporting its collaborations.

Sensei Biotherapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights

Retrieved on: 
Tuesday, August 9, 2022
Regulation of tobacco by the U.S. Food and Drug Administration, Primate, GLOBE, R, Science, Tumor-associated macrophage, Cancer, Northwest Biotherapeutics, IND, Research, ATP, Research and development, Blood, Patient, Company, Therapy, Tumor microenvironment, GMP, VSIG4, NASDAQ, Translation, Sixth, Survival, Conference, CD39, Food, Administration, VISTA, Investigational New Drug, Vaccine, Pharmaceutical industry, Fine chemical, Lithium

BOSTON, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer, today reported financial results for the second quarter ended June 30, 2022 and provided recent business updates.

Key Points: 
  • - On track with SNS-102 candidate selection, including generation of pH-sensitive parental antibodies -
    BOSTON, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer, today reported financial results for the second quarter ended June 30, 2022 and provided recent business updates.
  • We have also achieved a milestone with the generation of pH-sensitive antibodies for a second program targeting VSIG4.
  • In April 2022, Sensei presented preclinical data demonstrating that SNS-101 had a favorable pharmacokinetic profile in a single-dose mouse model.
  • Net Loss: Net loss was $10.5 million for the quarter ended June 30, 2022, compared to $9.8 million for the quarter ended June 30, 2021.